Zenas BioPharma (NASDAQ:ZBIO) Downgraded to “Sell” Rating by Wall Street Zen

Zenas BioPharma (NASDAQ:ZBIO) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Other equities research analysts have also issued reports about the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of Zenas BioPharma in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a report on Monday, December 29th. Evercore ISI started coverage on shares of Zenas BioPharma in a report on Wednesday, November 26th. They issued an “outperform” rating and a $55.00 target price for the company. Finally, Morgan Stanley downgraded shares of Zenas BioPharma from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $37.00 to $19.00 in a research report on Monday, January 5th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.14.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $16.08 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The company’s fifty day moving average price is $34.94 and its 200 day moving average price is $24.01. The stock has a market capitalization of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. Zenas BioPharma has a 1 year low of $5.83 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insiders Place Their Bets

In related news, CEO Leon O. Moulder, Jr. bought 50,000 shares of the company’s stock in a transaction on Wednesday, January 7th. The stock was bought at an average cost of $16.38 per share, with a total value of $819,000.00. Following the completion of the acquisition, the chief executive officer owned 316,155 shares in the company, valued at approximately $5,178,618.90. This represents a 18.79% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders acquired a total of 100,000 shares of company stock worth $1,639,000 over the last quarter. Corporate insiders own 16.50% of the company’s stock.

Institutional Investors Weigh In On Zenas BioPharma

Large investors have recently bought and sold shares of the stock. Quarry LP increased its stake in shares of Zenas BioPharma by 34.5% during the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after acquiring an additional 291 shares during the last quarter. Millennium Management LLC purchased a new stake in Zenas BioPharma in the third quarter valued at approximately $1,595,000. Bank of America Corp DE increased its position in Zenas BioPharma by 5.8% during the third quarter. Bank of America Corp DE now owns 14,809 shares of the company’s stock worth $329,000 after purchasing an additional 818 shares during the last quarter. Alliancebernstein L.P. raised its stake in Zenas BioPharma by 12.2% during the third quarter. Alliancebernstein L.P. now owns 18,350 shares of the company’s stock worth $407,000 after purchasing an additional 1,990 shares during the period. Finally, Creative Planning acquired a new position in shares of Zenas BioPharma in the 3rd quarter valued at $264,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.